NCT04428801View on ClinicalTrials.gov

Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2026

Conditions
COVID-19
Interventions
BIOLOGICAL

autologous adipose-derived stem cells

Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue

Sponsors
All Listed Sponsors
lead

Celltex Therapeutics Corporation

INDUSTRY